Sugi Predict

Sugi Predict / Compounds / SCHEMBL2768352

SCHEMBL2768352

SCHEMBL2768352

Cc1ccc(NC(=O)OC(C)(C)C)c2[nH]ccc12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ RAB9A P51151 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ GOT1 P17174 1/20 0.36
▸ BRD9 Q9H8M2 1/20 0.35
▸ LCK P06239 1/20 0.34
▸ CYP17A1 P05093 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ METAP1 P53582 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38664265 0.91 RAB9A (0.34) CA12CA1CA9SMN1; SMN2MAPT
SCHEMBL38663479 0.88 CA12 (0.38) CA12CA1CA9SMN1; SMN2MAPT
SCHEMBL29588945 0.85 HSP90AA1 (0.38) SMN1; SMN2RAB9ANPC1RXFP1LCK
SCHEMBL22531782 0.85 HSP90AA1 (0.38) SMN1; SMN2RAB9ANPC1RXFP1LCK
SCHEMBL2768424 0.85 AAK1 (0.39) CA12CA1CA9SMN1; SMN2MAPT
SCHEMBL23281864 0.80 AAK1 (0.37) CA12CA1CA9SMN1; SMN2MAPT
SCHEMBL25667793 0.79 BTK (0.46) CA1CA9MAPTRAB9ANPC1
SCHEMBL22778003 0.78 PTPRC (0.42) CA12CA1CA9SMN1; SMN2RAB9A
SCHEMBL24762761 0.77 MAPT (0.46) CA12CA1CA9SMN1; SMN2MAPT
SCHEMBL23281913 0.77 AAK1 (0.39) CA12CA1CA9SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
US-6673787-B2 PYRIMIDINESULFONAMIDE CONTAINING INDOLE COMPOUNDS USED AS ANTIANGIOGENIC AND ANTITUMOR AGENTS EISAI CO., LTD. (JP) 2004-01-06 — — US disclosed
CN-1132814-C Sulfonamide-containing indole compounds EISAI CO.,LTD. (JP) 2003-12-31 — — CN disclosed
US-6638964-B2 Pyridinesulfonamide containing indole compounds used as antiangiogenic and antitumor agents EISAI CO., LTD. (JP) 2003-10-28 — — US disclosed
CN-1396833-A Integrin expression inhibitors EISAI CO LTD (JP) 2003-02-12 — — CN disclosed
EP-1258252-A1 INTEGRIN EXPRESSION INHIBITORS Eisai Co., Ltd. (JP) 2002-11-20 — — EP disclosed
US-6469043-B1 ANTIANGIOGENIC AGENT WITH ANTITUMOR, ANTIMETASTATIC PROPERTIES WHICH SHOWS HIGH SAFETY EISAI CO., LTD. (JP) 2002-10-22 — — US disclosed
US-20020128483-A1 Sulfonamide-containing indole compounds EISAI CO., LTD. 2002-09-12 — — US disclosed
US-20020128480-A1 Sulfonamide-containing indole compounds EISAI CO., LTD. 2002-09-12 — — US disclosed
CN-1294579-A Sulfonamide-containing indole compounds EISAI CO LTD (JP) 2001-05-09 — — CN disclosed
EP-1074542-A1 SULFONAMIDE-CONTAINING INDOLE COMPOUNDS Eisai Co., Ltd. (JP) 2001-02-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CA12 4583/4885CA1 4622/4885CA9 3970/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CA12 4583/4885CA1 4622/4885CA9 3970/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CA12 4583/4885CA1 4622/4885CA9 3970/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CA12 4583/4885CA1 4622/4885CA9 3970/4885
US-20020128480-A1 Sulfonamide-containing indole compounds IDO1, HCCS, VEGFA CA12 183/4885CA1 188/4885CA9 169/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CA12 4583/4885CA1 4622/4885CA9 3970/4885
US-20020128483-A1 Sulfonamide-containing indole compounds IDO1, HCCS, VEGFA CA12 156/4885CA1 160/4885CA9 139/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CA12 4583/4885CA1 4622/4885CA9 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.